Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05068674 · ClinicalTrials.gov registry record · Phase 1
Human Embryonic Stem Cell-Derived Cardiomyocyte Therapy for Chronic Ischemic Left Ventricular Dysfunction
A Phase 1 study of Chronic Ischemic Left Ventricular Dysfunction, sponsored by Joseph C. Wu.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT05068674: Recruiting Phase 1 study of Chronic Ischemic Left Ventricular Dysfunction, sponsored by Joseph C. Wu.
NCT05068674 is a Phase 1 study of Chronic Ischemic Left Ventricular Dysfunction that is actively recruiting participants, run by Joseph C. Wu. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05068674, a Phase 1 study of Chronic Ischemic Left Ventricular Dysfunction, is actively recruiting participants, sponsored by Joseph C. Wu.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical study will utilize a new cell therapy approach (Human embryonic stem cells derived cardiomyocytes or hESC-CMs) to improve survival and cardiac function in patients with chronic left ventricular dysfunction secondary to MI (Myocardial Infarction).
Primary Outcome
The primary endpoints are safety and feasibility. The feasibility of preparing and delivering the study product, as well as collecting cardiac MRI variables in subjects will be assessed.
Conditions Studied
Interventions
- DRUG Human Embryonic Stem Cell-Derived Cardiomyocyte 50M cells
- DRUG Human Embryonic Stem Cell-Derived Cardiomyocyte 150 cells
- DRUG Human Embryonic Stem Cell-Derived Cardiomyocyte 300M cells
Study Locations (1)
California
- Stanford Hospital and Clinics - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2022-03-22 |
| Est. Completion | 2028-10 |
| Phase | Phase 1 |
What NCT05068674 shows while recruiting
NCT05068674 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Chronic Ischemic Left Ventricular Dysfunction appearing as the primary indexed condition, and to 3 interventions - of which Human Embryonic Stem Cell-Derived Cardiomyocyte 50M cells is the first listed.
NCT05068674 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05068674 about?
NCT05068674 is a clinical study titled "Human Embryonic Stem Cell-Derived Cardiomyocyte Therapy for Chronic Ischemic Left Ventricular Dysfunction". This clinical study will utilize a new cell therapy approach (Human embryonic stem cells derived cardiomyocytes or hESC-CMs) to improve survival and cardiac function in patients with chronic left ventricular dysfunction secondary to MI (Myocardial Infarction).
What is the current status of trial NCT05068674?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2022-03-22. Estimated completion is 2028-10.
What conditions does trial NCT05068674 study?
This clinical trial studies the following conditions: Chronic Ischemic Left Ventricular Dysfunction.
What interventions are being tested in trial NCT05068674?
The interventions under investigation include: Human Embryonic Stem Cell-Derived Cardiomyocyte 50M cells (DRUG), Human Embryonic Stem Cell-Derived Cardiomyocyte 150 cells (DRUG), Human Embryonic Stem Cell-Derived Cardiomyocyte 300M cells (DRUG).
Who is sponsoring clinical trial NCT05068674?
This trial is sponsored by Joseph C. Wu, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05068674 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05068674's enrollment target sits among peer trials
18 1721st of 2000 higher than 216 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI